Summary

The invention describes the use of microglia inhibitors for the manufacturing of medications, which inhibit the monocyte mediated, macrophage mediated, and T cell mediated immune reactions, as well as their application for the treatment of T cell mediated immune diseases and not T cell mediated inflammatory reactions.